阿扎胞苷联合维奈克拉方案在老年初治急性髓系白血病治疗中的临床效果研究  

The Clinical Efficacy of Azacitidine Combined with Venetoclax in the Treatment of Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

作　　者：魏文婷 WEI Wenting(Shanxi Health Vocational College,Jinzhong,Shanxi 030600)

机构地区：[1]山西卫生健康职业学院,山西晋中030600

出　　处：《智慧健康》2025年第1期92-95,共4页Smart Healthcare

摘　　要：目的 探究阿扎胞苷联合维奈克拉方案在老年初治急性髓系白血病(AML)治疗中的临床应用价值及其安全性评估。方法 本研究选取2022年1月—2024年4月在本院接受治疗的92例老年AML患者为研究对象。采用随机分组的方法,将符合纳入标准的患者分为两组,每组46例。其中,对照组应用阿扎胞苷治疗,实验组应用维奈克拉与阿扎胞苷进行联合治疗,对比两组治疗效果。结果 治疗后,实验组的总体缓解率显著提升至80.43%,该成效远超对照组的45.65%,且差异有统计学意义(P<0.05)。同时,实验组患者的干扰素γ(IFN-γ)水平实现明显提升,相较于对照组表现出显著优势;而肿瘤坏死因子(TNF-α)的浓度则得到有效控制,维持在较低水平。此外,实验组患者的血小板与白细胞计数均呈现上升趋势,且数值超过对照组;骨髓中原始细胞的比例亦有明显降低,低于对照组水平。上述各项指标的差异均具备统计学意义(P<0.05)。结论 在老年急性髓系白血病的初始治疗中,维奈克拉与阿扎胞苷的联合应用在安全性方面表现出显著的正面效果,未出现显著的不良反应,值得临床推广。Objective To deeply explore the clinical application value and safety evaluation of azacitidine combined with Venacla regimen in the treatment of acute myeloid leukemia (AML) in the elderly.Methods In order to evaluate the curative effect of different treatment schemes on 92 newly treated elderly patients with acute myeloid leukemia (AML),these patients were equally divided into two intervention groups,with 46 subjects in each group.Azacytidine was used as a single therapeutic drug in the control group;In the experimental group,venacla and azacytidine were used in combination therapy.Results After treatment,the overall remission rate of the experimental group significantly climbed to 80.43%,which greatly exceeded the control group's 45.65%,and the difference was statistically significant (P<0.05).In addition,the level of interferon (IFN-γ) in the experimental group was significantly improved,which had obvious advantages compared with the control group.However,the concentration of tumor necrosis factor (TNF-α) was effectively inhibited at a low level.The counts of platelets and leukocytes all showed an upward trend,surpassing the control group.The proportion of primordial cells in bone marrow was significantly lower than that in the control group,and the above differences were statistically significant (P<0.05).Conclusion For the elderly patients with acute myeloid leukemia,the combination of vinacala and azacytidine has outstanding safety,and no obvious adverse reactions have been observed,thus ensuring its high treatment safety.

关 键 词：老年 急性髓系白血病 初治 维奈克拉 阿扎胞苷 

分 类 号：R73[医药卫生—肿瘤]